Obstetricians and gynecologists' practice and opinions of expanded carrier testing and noninvasive prenatal testing

Prenatal Diagnosis

Volumn 34, Issue 2, 2014, Pages 145-152

  Benn, Peter ^a   Chapman, Audrey R ^b   Erickson, Kristine ^c   Defrancesco, Mark S ^a,d   Wilkins Haug, Louise ^e,f   Egan, James F X ^a   Schulkin, Jay ^g  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^b UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

^c AMERICAN UNIVERSITY   (United States)

^d Women's Health Connecticut   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f HARVARD MEDICAL SCHOOL   (United States)

^g American Congress of Obstetricians and Gynecologists   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL PRACTICE; FEMALE; GENETIC SCREENING; GYNECOLOGY; HEALTH PERSONNEL ATTITUDE; HETEROZYGOTE DETECTION; HUMAN; MALE; OBSTETRICS; PREGNANCY; PRENATAL DIAGNOSIS; QUESTIONNAIRE;

ATTITUDE OF HEALTH PERSONNEL; FEMALE; GENETIC TESTING; GYNECOLOGY; HETEROZYGOTE DETECTION; HUMANS; MALE; OBSTETRICS; PRACTICE PATTERNS, PHYSICIANS'; PREGNANCY; PRENATAL DIAGNOSIS; SURVEYS AND QUESTIONNAIRES;

EID: 84895071011     PISSN: 01973851     EISSN: 10970223     Source Type: Journal    
DOI: 10.1002/pd.4272     Document Type: Article

References (35)

1. Ram KT, Klugman SD. Best practices: antenatal screening for common genetic conditions other than aneuploidy. Curr Opin Obstet Gynecol 2010;22:139-45.
2. Grody WW, Cutting GR, Watson MS. The cystic fibrosis 'arms race': when less is more. Genet Med 2004;6:387-91.
3. Grody WW. Expanded carrier screening and the law of unintended consequences: from cystic fibrosis to fragile X. Genet Med 2011;13:996-7.
4. Lazarin GA, Haque IS, Nazareth S, et al. An empirical estimate of carrier frequencies for 400+ causal Mendelian variants: results from an ethnically diverse clinical sample of 23, 453 individuals. Genet Med 2013;15:178-86.
5. Bell CJ, Dinwiddie DL, Miller NA, et al., Carrier testing for severe childhood recessive diseases by next-generation sequencing. Sci Transl Med 2011;3:65ra4.
6. Kingsmore S. Comprehensive carrier screening and molecular diagnostic testing for recessive childhood diseases. PLoS Curr. 2012;4:e4f9877ab8ffa9.
7. Schrijver I, Aziz N, Farkas DH, et al. Opportunities and challenges associated with clinical diagnostic genome sequencing: a report of the Association for Molecular Pathology. J Mol Diagn 2012;14:525-40.
8. Bianchi DW. From prenatal genomic diagnosis to fetal personalized medicine: progress and challenges. Nat Med 2012;18:1041-51.
9. Moise KJ Jr, Boring NH, O'Shaughnessy R, et al. Circulating cell-free fetal DNA for the detection of RHD status and sex using reflex fetal identifiers. Prenat Diagn 2013;33:95-101
10. Devaney SA, Palomaki GE, Scott JA, Bianchi DW. Noninvasive fetal sex determination using cell-free fetal DNA. JAMA 2011;306: 627-36.
11. Benn P, Cuckle H, Pergament G. Non-invasive prenatal testing for aneuploidy: current status and future prospects. Ultrasound Obstet Gynecol 2013;42:15-33.
12. Kitzman JO, Snyder MW, Ventura M, et al. Noninvasive whole-genome sequencing of a human fetus. Sci Transl Med 2012;4:137ra76.
13. Stoll K, Resta R. Considering the cost of expanded carrier screening panels. Genet Med 2013;15:318-9.
14. Devers PL, Cronister A, Ormond KE, et al. Noninvasive prenatal testing/noninvasive prenatal diagnosis: the position of the National Society of Genetic Counselors. J Genet Couns 2013;22;291-5.
15. Morgan MA, Driscoll DA, Mennuti MT, Schulkin J. Practice patterns of obstetrician-gynecologists regarding preconception and prenatal screening for cystic fibrosis. Genet Med 2004;6:450-5.
16. Prior TW. Professional Practice and Guidelines Committee. Carrier screening for spinal muscular atrophy. Genet Med 2008;10:840-2.
17. ACOG Committee on Genetics. ACOG committee opinion No. 432: spinal muscular atrophy. Obstet Gynecol 2009;113:1194-6.
18. Gross SJ, Pletcher BA, Monaghan KG, Professional Practice and Guidelines Committee. Carrier screening in individuals of Ashkenazi Jewish descent. Genet Med 2008;10:54-6.
19. ACOG Committee on Genetics. ACOG committee opinion. Number 298, August 2004. Prenatal and preconceptional carrier screening for genetic diseases in individuals of Eastern European Jewish descent. Obstet Gynecol 2004;104:425-8
20. Grody WW, Thompson BH, Gregg AR, et al. ACMG position statement on prenatal/preconception expanded carrier screening. Genet Med 2013;15:482-3.
21. Green RC, Berg JS, Grody WW, et al. ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. Genet Med 2013;15:565-74.
22. Palomaki GE, Kloza EM, Lambert-Messerlian GM, et al. DNA sequencing of maternal plasma to detect Down syndrome: an international clinical validation study. Genet Med 2011;13:913-20.
23. Wilson KL, Czerwinski JL, Hoskovec JM, et al. NSGC practice guideline: prenatal screening and diagnostic testing options for chromosome aneuploidy. J Genet Couns 2013;22:4-15.
24. American College of Obstetricians and Gynecologists Committee on Genetics. Committee opinion no. 545: noninvasive prenatal testing for fetal aneuploidy. Obstet Gynecol 2012;120:1532-4.
25. Gregg AR, Gross SJ, Best RG, et al. ACMG statement on noninvasive prenatal screening for fetal aneuploidy. Genet Med. 2013; 15:5:395-8.
26. Benn P, Borell A, Chiu R, et al. Position statement from the Aneuploidy Screening Committee on behalf of the Board of the International Society for Prenatal Diagnosis. Prenat Diagn 2013;33:622-9.
27. Allyse, MA, Sayres, LC, Havard, BA, et al. Best ethical practices for clinicians and laboratories in the provision of non-invasive prenatal testing. Prenat Diagn 2013;33:656-61.
28. Benn P, Cuckle H, Pergament E. Non-invasive prenatal diagnosis for Down syndrome: the paradigm will shift, but slowly. Ultrasound Obstet Gynecol 2012;39:127-30.
29. Zimmermann B, Hill M, Gemelos G, et al. Noninvasive prenatal aneuploidy testing of chromosomes 13, 18, 21, X, and Y, using targeted sequencing of polymorphic loci. Prenat Diagn 2012;32:1233-41.
30. Presidential Commission for the Study of Bioethical Issues. Privacy and progress in whole genome sequencing. http://bioethics.gov/cms/sites/default/files/PrivacyProgress508_1.pdf accessed 02/24/2013.
31. Benn PA, Chapman AR. Ethical challenges in providing noninvasive prenatal diagnosis. Curr Opin Obstet Gynecol 2010;22:128-34.
32. Gliklich RE, Dreyer NA, editors. Registries for Evaluating Patient Outcomes: A User's Guide (2nd edn), Rockville (MD): Agency for Healthcare Research and Quality (US); 2010. http://www.ncbi.nlm.nih.gov/books/NBK49452/ Accessed 02/24/2013.
33. Carmichael M. A spot of trouble. Nature 2011;475:156-8.
34. Ready K, Haque IS, Srinivasan BS, Marshall JR. Knowledge and attitudes regarding expanded genetic carrier screening among women's healthcare providers. Fertil Steril 2012;97:407-13.
35. Cuckle H, Benn P, Pergament E. Maternal cfDNA screening for Down syndrome - a cost sensitivity analysis. Prenat Diagn 2013;33:636-42.